drugset / Trial / NCT02882100

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

NCT02882100

RandomizedParallel-groupSingle-blindPrevention

Summary

This study is powered to prospectively evaluate the relative effectiveness of adjuvanted trivalent influenza vaccine (aTIV; FLUAD) in preventing influenza mortality, hospitalization, and functional decline in a nursing home population in the U.S., compared to the commercially available, standard dose trivalent seasonal influenza vaccine (TIV; Fluvirin).

Timeline

Start
2016-04
Primary completion
2018-10-04
Completion
2023-01-25

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluad Vaccine
Subject Influenza Virus Vaccine Vaccine

Indications